HK Stock Market Move | TYK MEDICINES-B(02410) rose more than 12% during trading, market focus on progress of core product TY-9591.

TYK MEDICINES-B(02410) rose more than 12% during the trading session, up 7.16% to 14.21 Hong Kong dollars by the time of publication, with a trading volume of 1.32 billion Hong Kong dollars. On the news front, at the World Lung Cancer Congress in September this year, the clinical trial phase II of AITONIB tablets developed by Tongyuan Kang Medical for the treatment of brain metastases from non-small cell lung cancer has attracted high attention from peers. It is reported that AITONIB tablets (TY-9591) is a highly selective small molecule inhibitor developed by Tongyuan Kang Medical for EGFR classical mutations. The company has enrolled 224 patients who have completed conditional approval for listing by November 2024 and submitted a Pre-New Drug Application (Pre-NDA) in April 2025, with plans to formally submit a conditional listing application (NDA) in the fourth quarter of 2025. Pacific Securities previously pointed out that third-generation EGFR-TKI drugs have become the cornerstone of targeted therapy for lung cancer, and drug development in this area is now very active. Patients still face the issue of EGFR-TKI resistance, and solutions to resistance will have more investment value.